DBV Technologies reported $-33.48M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 20.31M 15.44M Dec/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amarin USD 12.54M 28.57M Jun/2025
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
DBV Technologies USD -33.48M 5.55M Sep/2025
Esperion Therapeutics USD -9.93M 24.99M Sep/2025
Galectin Therapeutics USD -7.42M 819K Dec/2021
Halozyme Therapeutics USD 219.57M 197.66M Mar/2026
Incyte USD 367.97M 46.53M Mar/2026
Insmed USD -148.3M 165.88M Mar/2026
Ionis Pharmaceuticals USD -200.02M 42.89M Dec/2025
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
PTC Therapeutics USD -70.99M 91.62M Dec/2025
Sarepta Therapeutics USD -252.2M 84.16M Dec/2025
Ultragenyx Pharmaceutical USD -99.43M 57.35M Dec/2025
United Therapeutics USD 379.5M 83.4M Dec/2025